ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride 2.5 mg - oromucosal solution - midazolam - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. for infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride 5 mg - oromucosal solution - midazolam - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. for infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride 7.5 mg - oromucosal solution - midazolam - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. for infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - midazolam as hydrochloride 10 mg - oromucosal solution - midazolam - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. for infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - suspension - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, and g4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rorateq should be administered betwen 6 and 12 weeks of age.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as hydrate - ג'ל - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as hydrate 50 mcg / 1 g - betamethasone - betamethasone - topical treatment of psoriasis vulgaris on the scalp and topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults 18 years of age and older.

ישראל - עברית - Ministry of Health

teva israel ltd - hydrocortisone; neomycin as sulfate - משחה - neomycin as sulfate 0.5 %; hydrocortisone 2.5 % - hydrocortisone and antibiotics - hydrocortisone and antibiotics - allergic dermatoses and other corticosteroid responsive inflammatory skin diseases including atopic dermatitis, contact dermatitis, seborrheic dermatitis, anogenital pruritus, infantile eczema and external otitis.

ישראל - עברית - Ministry of Health

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.